MAP2K1 and B-cell chronic lymphocytic leukemia: This notion is illustrated by our recent studies demonstrating that inhibition of MEK1/2 by binimetinib is effective against CLL cells when combined with an AKT inhibitor[111] or a BH3-mimetic[70].